Barclays
KZIA

Barclays’s Kazia Therapeutics KZIA Stock Holding History

Barclays’s Portfolio KZIA Stock Details KZIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$179K Hold
23,999
– – ﹤0.01% 3756
2025
Q4 		$165K Sell
23,999
-1
-0% -$9 ﹤0.01% 4417
2025
Q3 		$173K Hold
24,000
– – ﹤0.01% 4399
2025
Q2 		$150K Hold
24,000
– – ﹤0.01% 4414
2025
Q1 		$93.9K Hold
24,000
– – ﹤0.01% 4431
2024
Q4 		$212K Buy
+24,000
New +$555K ﹤0.01% 4279

Other funds holding KZIA

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $8.39B AUM 37.75% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Barclays's KZIA Position: Q1 2026 in Review

Barclays held its Kazia Therapeutics (KZIA) position steady in Q1 2026 at 23,999 shares worth $179K. The position accounts for ﹤0.01% of the portfolio, ranked #3756.

Barclays first reported a position in KZIA in Q4 2024 and has held it in 6 quarters since. The position peaked at $212K in Q4 2024. 23 funds tracked by Wall St. Rank hold KZIA as of Q1 2026.

  • Barclays held 23,999 shares of Kazia Therapeutics worth $179K as of Q1 2026.
  • Barclays left its Kazia Therapeutics share count unchanged in Q1 2026.
  • Kazia Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3756 holding.
  • Barclays first reported a position in Kazia Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Barclays's Kazia Therapeutics position peaked at $212K in Q4 2024.
  • 23 funds tracked by Wall St. Rank held Kazia Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.